The headline reads as positive (80% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › EXEL
Exelixis, Inc. (EXEL) stock analysis
WEAK BUY 20% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Exelixis, Inc. (EXEL) WEAK BUY with 20% confidence at a price of $66.20. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$66.20
Technical picture
The 14-day RSI is 82, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.3x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $47.24 and the swing low is $39.71; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 2.56, which looks expensive relative to its growth.
The company reports a profit margin of 35.3% and revenue growth of +10.6%.
In its latest quarter it earned $0.91 per share, which beat the $0.87 analysts expected, with revenue +10.6% year over year.
Wall Street's average rating is 2.3 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $55.53.
Trade plan from the model
The model's long / bullish plan uses an entry near $66.20, a target of $68.47 (+3.4%) and a stop-loss at $63.16 (-4.6%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 8, 2026 whatever the price does.
Entry$66.20
Target$68.47
Stop-loss$63.16
Reassess byNov 8, 2026
Research notes
Exelixis’ bull case is strong cabozantinib execution—franchise revenue rose 10% year over year to $1.73 billion through the first nine months of 2026—plus $840 million of operating cash flow, a sizable cash position, and four Phase 3 zanzalintinib trials that could diversify growth. The bear case is concentration in cabozantinib, ongoing patent challenges—including a pivotal November 2026 trial—and newly approved follow-on competition that could pressure exclusivity, pricing, and market share. A major recent catalyst is the FDA’s extended review of zanzalintinib in metastatic colorectal cancer, with a decision now expected by March 2027; shares have already gained roughly 223% over three years, raising execution and valuation expectations.
The model's one-paragraph read
Leans BUY — composite score +0.20 (WEAK BUY). Technicals: RSI 81.83, MACD bullish, price above SMA50. Fundamentals: PEG 2.56, margin 35.3%, revenue growth 10.6%. Financial results: YoY revenue +10.6%, last EPS surprise +4.6%. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Internet research: Exelixis’ **bull case** is strong cabozantinib execution—franchise revenue rose 10% year over year to $1.73 billion through the first nine months of 2026—plus $840 million of operating cash flow, a sizable cash position, and four Phase 3 zanzalintinib trials that could diversify growth. The **bear case** is concentration in cabozantinib, ongoing patent challenges—including a pivotal November 2026 trial—and newly approved follow-on competition that could pressure exclusivity, pricing, and market share. A major recent catalyst is the FDA’s extended review of zanzalintinib in metastatic colorectal cancer, with a decision now expected by March 2027; shares have already gained roughly 223% over three years, raising execution and valuation expectations. Suggested levels: entry $66.2, target $68.47, stop-loss $63.16, exit by 2026-11-08 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for EXEL
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | WEAK BUY | 20% | $66.20 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on EXEL
Oct 29, 2026 · Exelixis Matches The Whisper As Cabometyx Growth Accelerates, But Zanzalintinib Delays And Flat Guidance Temper A Stock Near Its Highs
- Oct 29, 2026: Exelixis Matches The Whisper As Cabometyx Growth Accelerates, But Zanzalintinib Delays And Flat Guidance Temper A Stock Near Its Highs (Earnings Whispers)
Frequently asked questions
Is EXEL a buy right now?
As of Oct 29, 2026, our automated model rates Exelixis, Inc. (EXEL) WEAK BUY with 20% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for EXEL?
The model's most recent plan targets $68.47 with a stop-loss at $63.16, from an entry near $66.20.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.